Nanobioconjugated paper/plastic platforms for improved diagnostics applications (NAP2DIAGNOSTICS)

Reference: MAT2014-52485-P

Project funded by MINECO (Spanish Government)

Period: 01/01/2015-31/12/2017

logo MINECO 2017

Summary:

There is an important gap between the current biosensing technologies and their real world applications as point-of-care devices which is hindering the transference of these devices to the market. The improvements of their efficiency, in terms of analytical performance such as reproducibility, sensitivity, detection limit, selectivity and range of response should go along with significant improvements in terms of cost and simplicity. In this context NAP2DIAGNOSTICS has as the main objective the development of cost/effective paper/plastic-based nanostructurated platforms with interest for diagnostics applications. This will be achieved through the use of new nanomaterials with excellent electrical/optical properties including actuation/motion capability (ex. nanomotors used as reagents to improve diffusion or capture/preconcentrate the analyte) at nanoscale level even at biological/physiological mediums, design and applications of innovative biosensing architectures in terms of microfluidics as well as a high integration level of materials and platforms. More in details, the first objective will be to study novel bioconjugated nanomaterials such as those derived from mono and bimetallic nanoparticles (including Au, Ir, Pd and Pt NPs) and graphene forms modified with antibodies, aptamers or DNA strands with excellent electrocatalytic/optical activity for their use as advantageous tags (signalling tools) so as to improve the performance of affinity biosensors (DNA, protein and cell sensors) and their easy adaptation to user-friendly devices (ex. minimize analytical steps including as much as possible the sample pre-treatment or use of hazardous reagents related to nanomaterials signalling/operation). Secondly NAP2DIAGNOSTICS will design and fabricate integrated plastic /paper (including bacterial cellulose) microfluidics platforms with enhanced biosensing capability. This will be achieved through the use of nanostructurated vaterite microparticles or nanoimprinted polymer-based pillar/hole areas (detection zones) as amplifiers of analyte preconcentration followed by its signalling in the case of lateral flow devices. In addition the design and application of novel modular-chip platforms will facilitate lab-on-a-chip application in real sample analysis. In addition by using ink-jet printing or highpressure nanomaterials transference technology, nano/microelectrodes fabrication at desired configurations, easy to be encapsulated within microfluidic platforms, will be achieved. Finally, NAP2DIAGNOSTICS will try to fill the gap between state-of-the-art nanobiosensing technologies and industrial needs. The development of new cost/efficient detection technologies and the improvements of paper/plasticbased nanobiosensing platforms including the increase of their technology readiness levels (TRL) will lead to more active collaborations with industry and participation in various H2020 projects with other partners in Spain and abroad and accelerate transfer of this technology to a possible spin-off.